MedPath

Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc. logo
🇨🇦Canada
Ownership
Public, Subsidiary
Established
2019-01-01
Employees
214
Market Cap
-
Website
http://ww.chinooktx.com

Clinical Trials

9

Active:2
Completed:1

Trial Phases

2 Phases

Phase 1:6
Phase 3:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials

Phase 1
6 (75.0%)
Phase 3
2 (25.0%)

Open-label Safety and PK Study of BION-1301 in Japanese Healthy Subjects

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
First Posted Date
2022-08-19
Last Posted Date
2023-01-11
Lead Sponsor
Chinook Therapeutics, Inc.
Target Recruit Count
36
Registration Number
NCT05508204
Locations
🇺🇸

Collaborative Neuroscience Research, LLC, Long Beach, California, United States

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CHK-336 in Healthy Volunteers

Phase 1
Terminated
Conditions
Healthy Volunteers
Interventions
Drug: Placebo
First Posted Date
2022-05-10
Last Posted Date
2023-11-03
Lead Sponsor
Chinook Therapeutics, Inc.
Target Recruit Count
88
Registration Number
NCT05367661
Locations
🇺🇸

Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States

Atrasentan in Patients With IgA Nephropathy

Phase 3
Active, not recruiting
Conditions
IgA Nephropathy
Immunoglobulin A Nephropathy
Interventions
Drug: Placebo
First Posted Date
2020-10-05
Last Posted Date
2024-10-11
Lead Sponsor
Chinook Therapeutics, Inc.
Target Recruit Count
404
Registration Number
NCT04573478
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Comprehensive Research Institute, Alhambra, California, United States

🇺🇸

Kidney Disease Medical Group, Glendale, California, United States

and more 131 locations

Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)

Phase 1
Terminated
Conditions
Multiple Myeloma
First Posted Date
2017-11-14
Last Posted Date
2021-04-01
Lead Sponsor
Chinook Therapeutics, Inc.
Target Recruit Count
21
Registration Number
NCT03340883
Locations
🇺🇸

James R. Berenson, MD, Inc, West Hollywood, California, United States

🇺🇸

Winship Cancer Institute/Emory University, Atlanta, Georgia, United States

🇺🇸

Ohio State University Wexner Medical Center James Cancer Hospital, Columbus, Ohio, United States

and more 4 locations

News

No news found
© Copyright 2025. All Rights Reserved by MedPath